Skip to content
2000
Volume 8, Issue 1
  • ISSN: 1871-5230
  • E-ISSN: 1875-614X

Abstract

Chronic inflammation represents a key pathogenetic event of many diseases, such as psoriasis, inflammatory bowel diseases, rheumatoid arthritis, asthma, multiple sclerosis, atherosclerosis, cystic fibrosis, and sepsis. Conventional therapies for many of these disorders do not lead to the resolution of the inflammatory disorder, and frequently are associated with limited effectiveness and severe side effects. For these reasons alternative therapies have been developed, in the attempt to ensure a more sustained therapeutic response. Biotechnological approaches for the development of these novel drugs are giving exciting results: several biologic molecules are now tested in preclinical or clinical trials, and several of them are even approved for marketing.

Loading

Article metrics loading...

/content/journals/aiaamc/10.2174/187152309787580793
2009-03-01
2025-05-24
Loading full text...

Full text loading...

/content/journals/aiaamc/10.2174/187152309787580793
Loading

  • Article Type:
    Research Article
Keyword(s): Inflammatory diseases; nucleic acid-based therapy; recombinant proteins
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test